639468-65-8

Basic information

• Product Name: 1-Boc-4-[(4-chlorophenyl)hydroxyMethyl]piperidine
• Synonyms: 1-Boc-4-[(4-chlorophenyl)hydroxyMethyl]piperidine;tert-butyl 4-((4-chlorophenyl)(hydroxy)methyl)piperidine-1-carboxylate
• CAS NO: 639468-65-8
• Molecular Formula: C₁₇H₂₄ClNO₃
• Molecular Weight: 325.83036
• Mol File: 639468-65-8.mol

Chemical Properties

• Boiling Point: 439.659°C at 760 mmHg
• Flash Point: 219.698°C
• Appearance: /
• Density: 1.193g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.55
• CAS DataBase Reference: 1-Boc-4-[(4-chlorophenyl)hydroxyMethyl]piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-4-[(4-chlorophenyl)hydroxyMethyl]piperidine(639468-65-8)
• EPA Substance Registry System: 1-Boc-4-[(4-chlorophenyl)hydroxyMethyl]piperidine(639468-65-8)

Safety Data

• Hazardous Substances Data: 639468-65-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Boc-4-[(4-chlorophenyl)hydroxyMethyl]piperidine is used as a building block for the preparation of pharmaceuticals and other bioactive molecules. Its unique structure and functional groups make it a valuable intermediate in the synthesis of various drug candidates.
Used in Organic Synthesis:
1-Boc-4-[(4-chlorophenyl)hydroxyMethyl]piperidine is used as a key intermediate in organic synthesis for the preparation of a wide range of compounds with potential applications in various fields, including medicine, agrochemicals, and materials science. Its versatility and reactivity enable the development of novel compounds with improved properties and functionalities.

InChI:InChI=1/C17H24ClNO3/c1-17(2,3)22-16(21)19-10-8-13(9-11-19)15(20)12-4-6-14(18)7-5-12/h4-7,13,15,20H,8-11H2,1-3H3

Upstream product

• 53220-41-0 4-(4-chlorobenzoyl)piperidine 
• 106-39-8 bromochlorobenzene 
• 137076-22-3 tert butyl 4-formylpiperidine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 25503-90-6 1-acetyl-piperidine-4-carboxylic acid 
• 59084-16-1 1-acetylpiperidine-4-carbonyl chloride 
• 59084-15-0 N-acetyl-4-(p-chlorobenzoyl)piperidine 
• 209808-06-0 tert-butyl 4-(4-chlorobenzoyl)piperidine-1-carboxylate 

Downstream Products

• 918501-81-2 tert-butyl 4-((4-chlorophenyl)(methoxy)methyl)piperidine-1-carboxylate 
• 918501-84-5 C₂₁H₃₁ClN₂O₄ 
• 918501-86-7 C₁₈H₂₆ClNO₅S 
• 918501-83-4 C₁₉H₂₆ClNO₄ 
• 209808-06-0 tert-butyl 4-(4-chlorobenzoyl)piperidine-1-carboxylate 

Relevant articles and documents

THERAPEUTIC COMPOUNDS

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which m, n, W, X, Y, Z, R, R1, R2, R3 and R4 are as defined in the specification, for use in therapy.

SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof : (I) in which m, n, W, X, Y, Z, R1, R2, R3 and R4 are as defined in the specification, for use in the treatm

5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS

Compounds of Formula I are useful for inhibiting AKT protein kinases. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. Formula (I).

Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists

Disclosed are compounds of the formula or a pharmaceutically acceptable salt thereof, wherein: M1 and M3 are CH or N; M2 is CH, CF or N; Y is —C(═O)—, —C(═S)—, —(CH2)q—, —C(═NOR7)— or —SO1-2—; Z is a bond or optionally substituted alkylene or alkenylene; R1 is H, alkyl, alkenyl, or optionally substituted cycloalkyl, aryl, heteroaryl, heterocycloalkyl or a group of the formula: where ring A is a monoheteroaryl ring; R1 is optionally substituted alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl; and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome nonalcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma or cognition deficit disorders using said compounds, alone or in combination with other agents.

[1H-PYRAZOLO[3, 4-D]PYRIMIDIN-4-YL]-PIPERIDINE OR -PIPERAZINE COMPOUNDS AS SERINE-THEORONINE KINASE MODULATORS (P70S6K, ATK1 AND ATK2) FOR THE TREATMENT OF IMMUNOLOGICAL, INFLAMMATORY AND PROLIFERATIVE DISEASES

The invention provides compounds of formula (I) and methods for inhibition of kinases, more specifically p70S6 kinases, and more preferably p70S6, Akt-1 and Akt-2 kinases. The invention provides compounds for modulating protein kinase enzymatic activity f

N-BENZYL-3-PHENYL-3-HETEROCYCLYL-PROPIONAMIDE COMPOUNDS AS TACHYKININ AND/ OR SEROTONIN REUPTAKE INHIBITORS

The present invention relates to heterocyclic derivatives of formula (1) wherein R1 represents a 5 or 6 membered heteroaryl group, in which the 5-membered heteroaryl group contains at least one heteroatom selected from oxygen, sulphur or nitrogen and the 6-membered heteroaryl group contains from 1 to 3 nitrogen atoms, or R1 represents a 4,5 or 6 membered heterocyclic group, wherein saids 5 or 6 membered heteroaryl or the 4,5 or 6 membered heterocyclic group may optionally be substituted by one to three substituents, which may be the same or different, selected from (CH2)pR6, wherein p is zero or an integer from 1 to 4 and wherein R and R2- R6 are each as defined in the description and pharmaceutically acceptable salts and solvates thereof; process for their preparation and their use in the treatment of conditions mediated by tachykinins and/or by selective inhibition of serotonin reuptake transporter protein.

Syntheses and Binding Studies of New [(Aryl)(aryloxy)methyl]piperidine Derivatives and Related Compounds as Potential Antidepressant Drugs with High Affinity for Serotonin (5-HT) and Norepinephrine (NE) Transporters

In a wide search program toward new, efficient, and fast-acting antidepressant drugs, we have prepared series of new compounds having an (aryl)(aryloxy)methyl moiety linked directly or through a methylene chain to different substituted and unsubstituted cycles (isoquinoline, piperazine, piperidine, tetrahydropyran, or cyclopentane). These compounds have been evaluated for their affinities for serotonin (5-HT) transporter (SERT) and 5-HT1A and 5-HT2A receptors. Racemic mixtures of 4-[(aryl)(aryloxy)methyl]piperidine derivatives showed much higher affinity values for SERT than fluoxetine and resulted in lack of affinity for 5-HT 1A and 5-HT2A receptors. Some of these racemic mixtures were resolved to their enantiomers and tested for binding to norepinephrine (NE) transporter (NET), dopamine (DA) transporter (DAT), and α2 receptor. Several of these enantiomers [(-)-15b, (-)-15j, (-)-15t, (+)-15u] displayed a dual binding profile with affinities for SERT and NET with K i i = 1.9 and 13.5 nM, respectively), and further pharmacological characterization is in progress for its evaluation as a antidepressant.